Nicolas Girard, MD, PhD

Nicolas Girard, MD, PhD, discusses patient-reported outcomes from the LUMINOSITY trial of telisotuzumab vedotin in NSCLC.

Nicolas Girard, MD, PhD, discusses the rationale of targeting PD-L1 and LAG-3 in NSCLC in the RELATIVITY-104 study.

Nicolas Girard, MD, discusses data from the phase 3 MARIPOSA trial of amivantamab-vmjw plus lazertinib for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

Nicolas Girard, MD, discusses how to maximize the clinical benefit of crizitonib (Xalkori) in non-small cell lung cancer (NSCLC).